USP16

Across TCGA pan-cancer cohorts, USP16 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated USP16 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher USP16 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated USP16 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and COAD are the cancer types where USP16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	1.000	0.807	.010	33	view →
PDAC	OS	Median	III,IV	0.963	0.573	.006	20	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
UCEC	DFS	Quartile	III,IV	0.419	0.880	.022	4	view →
HNSC	DFS	Median	II,III,IV	0.913	0.977	.038	2	view →
GBM	OS	Median	All	0.678	0.848	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

USP16–LUAD (OS)

Open the LUAD breakdown →